Shanghai Allist Pharmaceuticals Co., Ltd.
688578.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$37.13B
Close$
$190.25
143% upside
Current Fair Value
143% upsideUndervalued by 143% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $37.13 Billion |
|---|---|
| Enterprise Value | $36.03 Billion |
| Dividend Yield | $1.00 (1.45%) |
| Earnings per Share | $4.85 |
| Beta | 0.11 |
| Outstanding Shares | 450,000,000 |
Return
| Return on Equity | 31.65% |
|---|---|
| Return on Assets | 28.37% |
| Return on Invested Capital | 34.06% |
Valuation & Multiples
| P/E Ratio | 13.91 |
|---|---|
| PEG | 33.76 |
| Price to Sales | 6.02 |
| Price to Book Ratio | 4.35 |
| Enterprise Value to Revenue | 5.87 |
| Enterprise Value to EBIT | 12.45 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shanghai Allist Pharmaceuticals Co., Ltd.
2,272 employees
CEO: Jinhao Du Established in 2004, Shanghai Allist Pharmaceuticals Co., Ltd. is a Chinese enterprise dedicated to the innovation and development of medicinal products. Headquartered in Shanghai, the company focuses its efforts on creating therapeutic ...